AdvaMed Wants Across-The-Board Risk-Based Regulation For Diagnostics

Under an AdvaMed plan for expanding FDA regulation of diagnostic tests, tests that consist of new or unproven biomarkers on new technology platforms would likely require a pre-market approval application